Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 7
Submit an article Journal homepage
295
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

Raffaele PalmieriClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; View further author information
,
Sarah A. BuckleyClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; View further author information
,
Megan OthusPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; View further author information
,
Anna B. HalpernClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information
,
Mary-Elizabeth M. PercivalClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information
,
Bart L. ScottClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; View further author information
,
Paul C. HendrieDepartment of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ;Seattle Cancer Care Alliance, Seattle, WA, USA; View further author information
,
Pamela S. BeckerClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information
,
Vivian G. OehlerClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information
,
Elihu H. EsteyClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information
&
Roland B. WalterClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ;Department of Pathology, University of Washington, Seattle, WA, USA; ;Department of Epidemiology, University of Washington, Seattle, WA, USACorrespondence[email protected]
View further author information
 show all
Pages 1728-1731 | Received 01 Jan 2020, Accepted 07 Feb 2020, Published online: 20 Feb 2020

References

  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93(10):1267–1291.
  • Wrzesień-Kuś A, Robak T, Wierzbowska A, et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol. 2005;84(9):557–564.
  • Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80(2):115–126.
  • Halpern AB, Othus M, Huebner EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32(11):2352–2362.
  • Halpern AB, Othus M, Huebner EM, et al. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica. 2019;104(4):e143–e146.
  • Halpern AB, Walter RB. CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia. Oncotarget. 2018;9(93):36543–36544.
  • Bohl SR, Bullinger L, Rücker FG. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018;11(5):361–371.
  • Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007;13(14):4225–4232.
  • Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5(2):e9001.
  • Kurimoto M, Matsuoka H, Hanaoka N, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2013;27(1):233–235.
  • Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011;118(6):1472–1480.
  • Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6(8):6448–6458.
  • Halpern AB, Othus M, Huebner EM, et al. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia. 2017;31(12):2560–2567.
  • Leonard SM, Perry T, Woodman CB, et al. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia. PLoS One. 2014;9(1):e87475.
  • Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. JCO. 2011;29(33):4417–4423.
  • Grimwade D, Hills RK, Moorman AV, et al., on behalf of the National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354–365.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.